GeoVax Labs, Inc. has embarked on a pioneering research program to assess the immunogenicity and stability of its GEO-MVA vaccine when delivered through Vaxxas’ high-density microarray patch (HD-MAP) technology. This study, conducted at the University of Queensland, seeks to validate a needle-free, self-administered vaccine platform that could revolutionize pandemic preparedness and global immunization efforts.

The HD-MAP technology presents a promising alternative to traditional needle-and-syringe methods, offering benefits such as self-administration, increased patient acceptance, higher immunogenicity, and thermostability. These advantages could significantly enhance vaccine accessibility and efficiency, particularly in low- and middle-income countries where refrigeration and healthcare infrastructure may be limited.

David Dodd, Chairman and CEO of GeoVax, highlighted the potential of this program to meet global needs for more accessible and effective vaccines. The study’s success could pave the way for a thermostable, needle-free GEO-MVA vaccine, suitable for pandemic response, biodefense stockpiling, and routine immunization programs.

The Vaxxas HD-MAP platform has already shown enhanced immunogenicity in various studies, and GeoVax’s recent favorable scientific advice from the European Medicines Agency (EMA) supports a streamlined regulatory pathway for GEO-MVA. This development could expedite the vaccine’s approval and deployment, marking a significant milestone in the fight against infectious diseases.

Supported by GeoVax and led by researchers at the University of Queensland, this study represents a critical step forward in vaccine technology. By eliminating the need for needles and refrigeration, the GEO-MVA vaccine delivered via HD-MAP could offer a practical solution to global immunization challenges, ensuring rapid and efficient vaccine distribution in both routine and emergency settings.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is GeoVax Advances Needle-Free Vaccine Technology with HD-MAP Study.